Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300365 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00300365: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00300365 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300365, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a 12% greater increase in HDL-C when compared to niacin-ER monotherapy over 12 weeks in non-diabetic patients with the metabolic syndrome (see Table 1).
Interventions
- OTHER Placebo
- DRUG Aspirin
- DRUG Pioglitazone
- DRUG Niacin ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300365
The ClinicalTrials.gov registry entry for NCT00300365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00300365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300365 about?
NCT00300365 is a clinical study titled "Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL". We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a 12% greater increase in HDL-C when compared to niacin-ER monotherapy over 12 weeks in non-diabetic patients with the...
What is the current status of trial NCT00300365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2005-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00300365?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), Pioglitazone (DRUG), Niacin ER (DRUG).
Who is sponsoring clinical trial NCT00300365?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.